The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder

Table 2

Demographic and clinical features of responder and nonresponder patients.

Variable	Responder	Nonresponder	value
Gender (%)
Female	18 (78,3)	5 (21,7)	0,37
Male	7 (73,4)	4 (36,6)
Age mean (Min–Max)	8,64 (5–16)	11,44 (5–17)	0,11
Renal scar (%)
−	20 (29,9)	8 (11,9)	0,55
+	5 (62,5)	1 (12,5)
VDSS mean (Min–Max)
Before treatment	14,44 (10–25)	19,89 (8–28)	0,063
After treatment	2,28 (0–8)	14,11 (8–20)	<0,001
Filling phase symptoms mean (Min–Max)
Before treatment	4,85 (4–6)	5,1 (3–6)	0,084
After treatment	1,22 (0–3)	2,47 (2–4)	0,05
Voiding phase symptoms mean (Min–Max)
Before treatment	8,23 (5–10)	8,46 (6–9)	0,46
After treatment	2,34 (0–4)	3,48 (3–8)	0,045
Bladder volume (mL) mean (Min–Max)
Before treatment	167,08 (80–350)	214,67 (100–521)	0,48
After treatment	307,84 (120–600)	291,78 (130–526)	0,7